J M Strong

University of Illinois at Chicago, Chicago, Illinois, United States

Are you J M Strong?

Claim your profile

Publications (21)115.69 Total impact

  • Journal of Pharmacology and Experimental Therapeutics 05/1979; 209(1):20-4. · 3.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The pharmacokinetics of procainamide (PA) and N-acetylprocainamide (NAPA) were compared in 3 normal subjects after simultaneous intraveous injection of PA and NAPA-13C. The distribution kinetics of both compounds were modeled with a 3-compartment mamillary system, and it was found that their steady-state distribution volumes were not significantly different, averaging 1.41 L/kg for PA and 1.46 L/kg for NAPA. However, the intercompartmental clearances of NAPA were slower than those of PA. In these normal subjects, the average elimination t1/2 and total elimination clearance for PA were 2.5 hr and 589.8 ml/min, and for NAPA were 6.2 hr and 233.7 ml/min. Mean renal clearances of PA (346.7 ml/min) and of NAPA (199.5 ml/min) exceeded the usual rate of glomerular filtration, which suggests that both compounds are eliminated in part by renal tubular secretion. All subjects were phenotypic rapid acetylators of isoniazid and converted approximately one fourth of the administered PA dose to NAPA-12C. The fate of 15.4% of the administered PA and 14.5% of the administered NAPA-13C was not determined.
    Clinical Pharmacology &#38 Therapeutics 11/1977; 22(4):447-57. · 7.39 Impact Factor
  • Analytical Chemistry 11/1977; 49(12):1843-6. DOI:10.1021/ac50020a051 · 5.83 Impact Factor
  • Source
    J S Dutcher, J M Strong
    [Show abstract] [Hide abstract]
    ABSTRACT: We describe a routine method for determining concentrations of the antiarrhythmic drug procainamide and its active metabolite, N-acetylprocainamide, in plasma. A simple extraction of 1.0 ml of plasma is followed by separation and chromatographic analysis by use of a column containing microparticulate silica. p-nitro-N-(2-diethylaminoethyl)benzamide hydrochloride was synthesized and used as the internal standard. Total chromatographic time is only 7 min. The day-to-day CV during three months of daily use was less than 4% of the mean for each compound, and we saw no deterioration in column performance during this time. Phenobarbital, phenytoin, lidocaine, primidone, methsuximide, quinidine, and their metabolites do not interfere.
    Clinical Chemistry 08/1977; 23(7):1318-20. · 7.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ten patients with chronic premature ventricular contractions (PVCs) received short-term oral therapy with N-acetylprocainamide (NAPA) to determine its antiarrhythmic efficacy and side effects under the conditions of a placebo-controlled, dose-ranging trial. NAPA was effective in suppressing PVCs in 8 patients but caused a paradoxical increase in PVC frequency in one. Results were equivocal in the remaining patient because PVCs did not recur when NAPA therapy was withdrawn. Mean NAPA plasma levels as high as 41.1 microng/ml did not have untoward hypotensive or myocardial depressant effects, as judged by electrocardiographic and systolic time intervals. There was, in fact, a consistent reduction in PEP/LVET ratio, indicating that NAPA increases the force of myocardial contraction. The mean NAPA elimination half-life of 10.9 hr was longer than the 6.2 hr half-life reported for normal subjects, but its prolongation was predictably correlated with reductions in creatinine clearance. Gastrointestinal side effects experienced by 3 patients and insomnia noted by 2 patients are similar to known adverse reactions to procainamide.
    Clinical Pharmacology &#38 Therapeutics 06/1977; 21(5):575-87. · 7.39 Impact Factor
  • Arthur J. Atkinson, John M. Strong
    [Show abstract] [Hide abstract]
    ABSTRACT: Application of pharmacokinetic principles to patient therapy requires prior elucidation of the relationship between the plasma concentration of a drug and its pharmacological effects. This relationship is complicated by the fact that many drugs are converted to active metabolites so that observed effects represent a composite of the pharmacological activity of a drug and its metabolites. In fact, discrepancies between the observed duration of drug action and the biological half-life of a given drug should suggest that an active drug metabolite may have been formed. As is illustrated by the anticonvulsant drug methsuximide, drug metabolite levels may be so much higher than those of the parent drug that only the metabolite levels are of routine clinical significance. In other cases, levels of both the parent drug and one or more metabolites must be considered together and combined according to their relative potency to give an index of total pharmacological activity. This situation poses obvious difficulties with respect to the ease and safety of drug therapy with these agents. It generally would seem preferable to treat patients with drugs that are converted to inactive metabolites or are excreted largely unchanged.
    Journal of Pharmacokinetics and Biopharmaceutics 05/1977; 5(2):95-109. DOI:10.1007/BF01066214
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The conjugation of glycine to benzoates and the conjugation of L-glutamine to certain arylacetates are catalyzed by two different acyl-CoA:amino acid N-acyltransferases which can be purified separately from liver mitochondrial fractions of either rhesus monkey or man. In both species, one transferase is specific for glycine and the other for L-glutamine. The glycine enzyme utilizes either butyryl-CoA or benzoyl-CoA as acyl donors while the glutamine enzyme uses either phenylacetyl-CoA or indoleacetyl-CoA. Acyl-CoA substrates for one transferase do not serve as substrates for the other. Additional studies with the monkey liver enzymes revealed that acyl-CoA substrates for one transferase inhibit the other, that the apparent Km value is low (10(-6) to 10(-5) M range) for the preferred acyl-CoA substrate as compared to the amino acid acceptor (greater than 10(-2) M) and that both transferases have a molecular weight of approximately 24,000. Hippuric acid and either phenylacetylglutamine or indoleacetylglutamine were characterized as the products formed by the separate enzymes.
    Journal of Biological Chemistry 07/1976; 251(11):3352-8. · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oral administration of a 1.5-gm dose of N-acetylprocainamide (NAPA) to 9 patients with premature ventricular contractions (PVCs) confirmed previous indirect evidence that this metabolite of procainamide has antiarrhythmic efficacy and potency comparable to those of procainamide. Although the mechanism by which NAPA acts as an antiarrhythmic drug is not known, it was found that the 6 patients with coupled PVCs responded to NAPA therapy and that the 3 patients without coupled PVCs failed to respond. Coupling interval prolongation also occurred during NAPA therapy in 4 of the 6 responding patients. These observations suggest that NAPA may terminate coupled PVCs by slowing and then interrupting conduction of re-entrant impulses, as has been proposed for procainamide. NAPA plasma concentrations of 7.4-17.2 mug/ml were well tolerated by the patients and produced an average fall of 3 mm Hg in mean arterial pressure and a 7.6% mean increase in corrected QT interval.
    Clinical Pharmacology &#38 Therapeutics 06/1976; 19(5 Pt 1):508-14. · 7.39 Impact Factor
  • E C Rossi, J J Mieyal, J M Strong
    Molecular Pharmacology 12/1975; 11(6):751-8. · 4.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Absorption of a single oral dose of N-acetylprocainamide (NAPA) was studied in 3 normal subjects. Approximately 85% of the oral dose was absorbed and peak plasma NAPA concentrations were reached in 45 to 90 min. In 2 subjects, NAPA was absorbed at a fast initial rate, then more slowly, prolonging the apparent elimination phase half-life. Absolute bioavailability was determined by a new stable isotope method that entailed intravenous injection of NAPA 13C at the same time that an unlabeled NAPA capsule was given orally. Plasma levels and urine excretion of both compounds were determined by mass fragmentography. Bioavailability was assessed by deconvoluting the plasma level vs time curves resulting from intravenous and oral drug administration, and also by comparing the relative percentage of NAPA and NAPA-13C excreted unchanged in the 24 hr after simultaneous administration.
    Clinical Pharmacology &#38 Therapeutics 12/1975; 18(5 Pt 1):613-22. · 7.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The pharmacokinetics of N-acetylprocainamide (NAPA) have been studied in three normal subjects who received 500 mg of this compound by timed intravenous injection. Plasma N APA concentrations and urine excretion were measured by quadrupole mass fragmentography, and a three- compartment pharmacokinetic model was used for data analysis. NAPA elimination half-life and total distribution volume averaged 6.0 hr and 1.38 liters/kg, respectively. Renal excretion of unchanged NAPA accounted for 81% of its elimination, and the mean renal NAPA clearance was 179 ml/min. Approximately 2% of the injected NAPA was deacetylated to procainamide. The fate was not determined of 17% of the NAPA that was estimated to have been eliminated during the 16- hr study period.
    Journal of Pharmacokinetics and Biopharmaceutics 09/1975; 3(4):223-35. DOI:10.1007/BF01066919
  • Analytical Chemistry 08/1975; 47(9):1720-1721. DOI:10.1021/ac60359a043 · 5.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The kinetics of distribution and elimination of lidocaine and two of its metabolites, monoethylglycinexylidide (MEGX) and glycinexylidide (GX), were studied in 4 uremic patients on chronic hemodialysis. Each patient received a loading dose of 75 mg of lidocaine, followed by a 30 mug/kh/min lidocaine infusion. No toxic side effects from lidocaine were seen during the study. Average values for lidocaine steady-state plasma levels (2.3 mug/ml) clearance (12.3 ml/min/kg), terminal half-life (148 min), and total volume of distribution (1.9 L/kg) were found, and are similar to those values reported for normal subjects MFGX and after lidocaine infusion averaged 1/5-2/3 of the corresponding lidocaine level, as in nonuremic subjects, and plateaued by 6-8 hr. GX levels did not reach plateau by 12 hr and remained relatively unchanged after infusion. It is concluded that lidocaine infusion in uremic patients is safe, with no abnormal cumulation of lidocaine or MEGX. GX levels, however, may increase progressively, even after 12 hr.
    Clinical Pharmacology &#38 Therapeutics 08/1975; 18(1):59-64. · 7.39 Impact Factor
  • J Elson, J M Strong, W K Lee, A J Atkinson
    [Show abstract] [Hide abstract]
    ABSTRACT: Compared to procainamide in an animal arrhythmic model, the antiarrhythmic potency of the N-acetylated metabolite of procainamide (NAPA) was 92% with respect to dose and 70% with respect to plasma level. The antiarrhythmic effects of combinations of the drugs were additive. Measurements of procainamide and NAPA plasma levels needed to suppress ventricular extrasystoles suggested that both compounds are nearly equipotent in patients as well. The average plasma level required for arrhythmia control in these patients was equivalent to 5.1 mcg/ml procainamide. Since patients on long-term procainamide therapy have plasma concentrations of NAPA that are usually comparable to, and occasionally greater than, their procainamide levels, dose regiments based on procainamide levels alone need revision to include consideration of the levels of this metabolite.
    Clinical Pharmacology &#38 Therapeutics 03/1975; 17(2):134-40. · 7.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Glycinexylidide (GX) is a metabolite of lidocaine that is frequently present in mug/ml concentrations in the plasma of patients treated with lidocaine infusions for 24 hr or more. Plasma levels of GX have 26% the antiarrhythmic activity of lidocaine in an animal model, and GX adversely affects the mental performance of normal subjects at plasma concentrations comparable to those found in patients. The total volume of GX distribution in man is similar to that of lidocaine but the plasma clearance is less, so that the 10-hr elimination phase half-life of GX is much longer than the 1 1/2 hr half-life reported in normal subjects for lidocaine. About half of an administered dose of GX is excreted unchanged in urine, roughly 15% appears in urine as conjugates of xylidine and p-OH xylidine, and the fate of the rest is unknown.
    Clinical Pharmacology &#38 Therapeutics 03/1975; 17(2):184-94. · 7.39 Impact Factor
  • A J Atkinson, J M Strong
    Acta pharmaceutica Suecica 01/1975; 11(6):659.
  • J M Strong, T Abe, E L Gibbs, A J Atkinson
    Neurology 04/1974; 24(3):250-5. DOI:10.1212/WNL.24.3.250 · 8.30 Impact Factor
  • J Blumer, J M Strong, A J Atkinson
    Journal of Pharmacology and Experimental Therapeutics 08/1973; 186(1):31-6. · 3.86 Impact Factor
  • J M Strong, M Parker, A J Atkinson
    Clinical Pharmacology &#38 Therapeutics 01/1973; 14(1):67-72. · 7.39 Impact Factor
  • Source
    Clinical Chemistry 08/1972; 18(7):643-6. · 7.77 Impact Factor